




ψ

- Wishard Memorial Hospital


# History of IU BMSCT Program 1985 Four-bed unit at Riley Hospital for Children at IU Health 1986 Autologous program initiated 1987 Adult program moved to IU Health University Hospital 1987 First unrelated donor transplant 1988 First peripheral blood stem cell transplant 1994 Riley Hospital for Children at IU Health opens Transplant unit 2003 Adult BMT Unit upgraded to new unit at current location 2007 Renovated Cellular Therapy Laboratory and Adult Apheresis 2008 IU Simon Cancer Center opened a 28-bed heme/onc/BMT unit 2011 Simon Family Tower at Riley Hospital for Children


#### Adult IU BM/SCT Facility


- 13-bed adult inpatient HEPA-filtered unit (ICU monitoring capabilities) at University Hospital
- 28-bed adult inpatient heme/onc/BMT unit in the IU Simon Cancer Center
- Dedicated HEPA-filtered BMT Outpatient Clinic



dult Clinical Team		Щ
	Adult	l
Attending Physicians	7	
Transplant Coordinators	4.5	
Nurse Practitioners	3.5	
Pharm D	2	
Nutritionist	1	
Financial Coordinator	0.5	
Social Workers	1	
Research Nurse	1.5	
Data Management	4	







#### Germ Cell Tumor Definition

- A tumor arising from sperm or the eggs within the ovary
- Extragonadal primary
  - Primary mediastinal
    - Poor prognosis
  - Retroperitoneal
  - Similar prognosis as primary testicular cancer
- Ovarian cancer is different than Ovarian GCT
- Primary testicular GCT

#### Introduction

ψ


#### Щ

- The most common solid malignancy affecting males between the ages of 15 and 35
- Germ cell tumors account for 95% of testicular cancers
- Prior to the late 70s, five-year survival was 64%
- In 2011, five-year survival is over 95%

#### Epidemiology

 Relatively uncommon - 1% of male malignances in the United States ψ

- · Scandinavian countries have the highest incidence
- Rare in African-Americans
- Primary age group is 15-35 for non-seminomatous germ cell tumor (NSGCT) and a decade older for seminoma
- For 2011 estimated new cases 8,290, deaths 350 (American Cancer Society: Cancer Facts and Figures 2011 Atlanta, GA: American Cancer Society, 2011)



ψ

## Clinical Manifestations Nodule or painless swelling of one testicle Dull ache or heavy sensation in the lower abdomen Symptoms of metastatic disease relate to site of disease Neck mass Cough, dyspnea and hemoptysis Gastrointestinal symptoms Back pain (bulky retroperitoneal disease)

CNS symptoms


### Fertility • At time of diagnosis 10-35% are sterile – Treatment induced sterility:

- Abdominal radiotherapy, RPLND, chemotherapy
- Chemotherapy = 71% rate of fathering a child
- Chemotherapy + radiation = 67%
- Risk factors for azoospermia:
  - Radiation therapy
  - Age > 30 years
  - Chemotherapy duration > 6 months
- SPERM BANKING DISCUSSION !!!!

Pliarchopoupou K, et al. CancerTreat Rev. 2010; 36:262-67.


#### ψ Initial Staging and Disease Evaluation • Scrotal ultrasound Serum tumor markers Beta-hCG AFP • . . LDH Radiographic imaging Abdominal/pelvic CT scan CXR then CT if indicated PET scans • Radical inguinal orchiectomy Pathology evaluation of tumor

## Pure Seminoma Slightly older age group AFP is not elevated Beta-hCG is elevated in fewer than 20% of cases Good and intermediate prognostic categories only Treatments may include: Surgery Chemo Radiotherapy




- Choricarcinomas
- Mix cell type
- Elevated AFP or Beta-hCG
- Good, intermediate and poor prognostic categories
- Treatments include:
  - SurgeryChemotherapy


Risk Classification			
Risk Status	Non-Seminoma	Seminoma	
Good risk	Testicular or retroperitoneal primary No non-pulmonary mets AFP < 1,000 ng/mL hCG < 5, 000 IU/L LDH < 1.5 ULN	Any site, no non-pulmonary me Normal AFP Any hCG Any LDH	
Intermediate risk	Same as above with: AFP 1, 000-10,000 ng/mL hCG 5, 000-50,000 IU/L LDH 1.5-10 x ULM	Same as above, with non- pulmonary visceral metastase	
Poor risk	Non-pulmonary visceral metastases present (i.e. bone, liver, brain): AFP > 10,000 ng/mL hCG > 50,000 IU/L LDH < 10 x ULN	No patients classified as poor	




 Provides accurate pathological staging of the retroperitoneum



- Radiation Therapy
- High dose chemotherapy with peripheral blood stem cell transplant






#### **Referral Process**

- Patients are evaluated by our oncology germ cell team

   Lawrence Einhorn, MD
   Nasser Hanna, MD
- · Preliminary contact by telephone or email
- All clinical records including:
  - Serial tumor markers
  - Surgery reports
  - Pathology reports and slides for review
  - Radiology reports and films
- Weekly meetings between BMT and GCT team



Ronald McDonald House

#### Housing: Fair Haven Foundation

- Provides free housing to patients in need
- Foundation started by an IU Health employee
- Currently leases six apartments
- It is a Christian-based mission effort
- The Fair Haven Foundation name comes from the Mediterranean island of Fair Havens, where a storm-tattered ship once took refuge in the midst of terrible winds (Acts 27:8). Their prayer is that you would find refuge in the midst of the storm that you are facing.
- Contact information: <u>www.fairhavenfoundation.org</u>



ψ

ψ

ψ

#### Insurance Approval


Contact insurance company immediately and identify the decision maker

ψ

- Educate the insurance provider
- Have a form letter prepared to send to the insurance company with supporting articles and bibliography
- Make certain they understand it is a tandem transplant and obtain approval for both
- Submit an SOP and consult note
- Peer-to-peer reviews


### Stem Cell Transplant Work-up Local versus Indiana University Health Tests to be completed - in a timely fashion: - 12-lead EKG Predict KG


- PA and lateral CXR
- 24-hour urine collection for creatinine clearance
   Pulmonary functions with spirometry and diffusing capacity
- Sickle cell screen
- Infectious disease panel
- CMP, CBC, PT/PTT, INR
- Dental evaluation \* (red flag)
- Transplant MD consultation
- Information sheet and consent signatures




#### Mobilization and Stem Cell Collection


- · Filgrastim mobilization only
- Our dose is 10 mcg/kg/day rounded up to the nearest vial size
- A tunneled 28 cm 14 French double lumen catheter is placed for the collection and remains through out the tandem transplant process
- Collection of stem cells is initiated on day 5 of Filgrastim





ψ





#### Routine Lab Work

- · Beta-hCG and AFP on admission and weekly
- Daily CBC, CMP, magnesium and phosphorus
- Blood product transfusion:
  - Transfuse PRBC to keep Hgb >7
  - Transfuse platelets to keep > 10K

#### Chemo Cycle #2

ψ

ψ

• Typically begins 23-28 days after initiation of cycle #1

ψ

ψ

ψ

- Disease response to cycle #1 to qualify for cycle #2
- · Preparative regimen is identical
- · Dose modifications for toxicities
- · Delays between cycles should be avoided

#### ψ **Special Considerations** Progressive/refractory disease Not a contraindication to HDC "Induction" chemo not required to document chemo sensitivity Brain metastasis Not a direct contraindication to HDC Monitor platelet count closely during transplant Neuropathy Peripheral

- Otologic abnormalities
- Monitoring labs between cycle 1 and cycle 2 Magnesium and potassium levels
   CBC

#### Follow-up Care

- They do not require re-vaccination
- · They are returned to their primary oncologist
- · Follow-up with the IU GCT team about one month after recovery of blood counts
- Consideration at that time for:
  - Observation
  - Surgical resection of residual disease
  - Maintenance oral VP-16 in the NSGCT population

#### Case Study: Eric

- Eric is a 22 y.o. male college student in CA that presented to the local hospital with severe weakness
  - Hgb 5.0
  - Endoscopy to r/o GI bleed revealed a nodule in gastric area
  - CT demonstrated involvement of the lungs, liver and spleen
  - Brain MRI revealed 2 lesions
- Pathology from left orchiectomy confirmed the diagnosis of NSGCT
- Beta-hCG = 694,000 and AFP = 33.9
- Eric underwent four cycles of BEP: first cycle administered in CA, then he returned home to TN to complete his chemo
- At the end of chemotherapy Beta-hCG = 27

#### Case Study: Eric (continued) One month later his Beta-hCG had risen to 297

- Eric presented to IU for second opinion one day after the elevated tumor marker
- · Transplant work-up completed locally
- Stem cell collection delayed one week due to insurance issues
- · The day prior to initiating high dose chemo, patient seized due to progression of brain mets and was coded in the cafeteria
- After evaluation by neuro oncology, radiation oncology and medical oncology it was decided to proceed with the preparative regimen
- · Beta-hCG had gone up to 2,362 in just 2 weeks

#### Case Study: Eric (continued)

• Uneventful tandem transplant course with the second cycle being done as an outpatient

ψ

ψ

ψ

- Platelets were kept above 50K
- At completion of tandem transplant Beta-hCG, fell to 10.8 and brain metastasis improved
- He completed three cycles of oral VP-16
- Eight months out from chemo he had normal Beta-hCG
- One 2 cm lesion was treated with gamma knife radiosurgery 10 months after transplant



 49 y.o. male computer programmer who went to dinner and ate a lot of chicken wings March 2009

Ψ

Ψ

- Presented with severe right sided abdominal pain
   CT scan revealed left sided mass
- Testicular ultrasound + for left testis mass
- · Pathology from mass and testicle were pure seminoma
- Beta-hCG unusually high at 8,000
- Received three cycles of BEP and one cycle EP ending in June 2009
- Beta-hCG normalized and had an appropriate radiographic response by CT and PET scan

#### Case Study: John (continued)

- December 28, 2009 consult with Dr. Einhorn due to Beta-hCG elevation and PET scan + for recurrent disease
- Options:
  - Four courses SDC = 70% cure rate
    - Tandem transplant offering a 50% cure rate as third line therapy
  - One course VeIP followed by tandem transplant
    - 24/26 disease-free (two-year minimum follow-up)

#### Case Study (continued)

- Received cycle one February 7th-28th, 2010
- Received cycle two March 11th-28th, 2010
- May 23, 2010 = normal PET scan and normal Beta-hCG
- June 20, 2010 follow-up visit with Dr. Einhorn
  - Continued peripheral neuropathy
  - Slight hearing impairment
  - RTC in one year CT scans every four months, CXR every two months with tumor markers

Quoted a 90% cure rate at this juncture

#### **Take-Home Points**


- · Testicular cancer is a rare disease
- Be proactive with the insurance
- Timing is of the essence
- Oncology germ cell team should have an integral role throughout the transplant process
- Tandem transplant is the goal
- Widespread metastatic and refractory disease can be cured

### Contact Information

- www.iuhealth.org
- General telephone to schedule a consultation 317.944.0920
- GCT program contact information
  - Lawrence Einhorn, MD leinhorn@iupui.edu
  - Nasser Hanna, MD <u>hanna@iupui.edu</u>
  - Jackie Brames, RN <u>mjbrames@iupui.edu</u>

#### Transplant program contact information

- Rafat Abonour, MD <u>rabonour@iupui.edu</u>
- Jay Baute, RN jbaute1@iuhealth.org





ACTINOMYCIN-D-50 years ago	<b>U</b>
• 50% response rate, including 20% C.R.'s	10-
• Most relapses occurred within o year	ne
• 5-10% cure rate	


	HISTORICAL PERSPECTIVES
•	Single agent studies with Vinblastine + Bleomycin achieved results similar to Actinomycin-D
•	Vinblastine + Bleomycin synergistic in pre- clinical systems; initial studies in testicular cancer produced a 25% cure rate
•	Platinum (cisplatin) produced 3 complete and 3 partial responses in 11 patients with refractory testicular cancer

# <u>"ORIGINAL" PVB</u> Cisplatin 20 mg/M<sup>2</sup> x 5 q 3 weeks x 4 Vinblastine 0.2 mg/kg x 2 q 3 weeks x 4 Bleomycin 30 units weekly x 12 maintenance Vinblastine 0.3 mg/kg monthly x 21 .


<u>RESULTS – FIRST PVB STUDY</u> 40 years ago		<u>Щ</u>
Complete remission	33/47 (70%)	
Partial remission	14/47 (30%)	
Disease-free with		
PVB + surgery	5/47 (11%)	
30/47 (64%) 5 year	survival	
27/47 (57%) NED		









SECSG GU332: PVB VERSUS BEP		
	<u>PVB</u>	<u>BEP</u>
Number patients		123
C.K.		74 (00%)
NED with surgery		28 (23%)
Continuously NED	80 (66%)	96 (78%)





RESULTS (cont'd)			
	Standard Dose (%)	Double <u>Dose (%)</u>	
Relapse		3 (6.0)	
Continuously NED		46 (62.2)	
Presently NED	51 (66.2)	49 (66.2)	



#### <u>BEP VERSUS HIGH DOSE CHEMOTHERAPY\*</u>

- 174 poor risk and 45 intermediate risk patients (n= 219)
  randomized to BEP x 4 versus
  DEP x 2 followed by 2 courses of high dose consumption with store cell thereplace
- C.R. falls identical (55% versus 54%)
- 2 year overall survival 72% versus 71%

#### CISPLATIN PLUS VP-16 AS INITIAL SALVAGE CHEMOTHERAPY-The Early days

- SECSG Protocol: Induction chemotherapy PVB
- 19 of 44 patients (43%) achieved an NED status
- 10 of 44 (23%) continuously NED 20-39 months

J Clin Oncol 3:666, 1985

#### SALVAGE THERAPY OPTIONS FOR

- High dose chemotherapy with peripheral blocd stem cell transplant
- VeIP or TIP x 4 cycles
  - Salvage surgery

# <u>PITFALLS IN SALVAGE THERAPY</u> Elevated HCG or AFP as only evidence of relapse or progressive disease Plotear in decline of HCG Sanctuary sites

#### PITFALLS IN SALVAGE THERAPY (cont'd)


- Growing teratoma
- Pseudonodules on chest x-ray or ET due to bleomycin
- Special consideration: PMNSGCT or late relapse


## Prognostic Factors for High Dose Chemotherapy Those likely to <u>not</u> benefit from HDC: Primary mediastinal GCT refractory to initial and salvage chemotherapy Refractory disease Rising markers or radiographic evidence of progression within 4 weeks of cisplatin High β-HCG levels


#### The case for HDC as Salvage therapy

- Poor risk patients = not the same high rate of cure as good and intermediate risk (50%)
- GCT's are highly responsive to chemotherapy
- High dose chemo as 3<sup>rd</sup> line salvage therapy – 10-20% cure rate
- Improved supportive care
- Patient's age permits use of high dose chemotherapy with improved safety profile

Bosl GJ. Cancer of the Testis. In: DeVita eds. (Title of book): edition.







Ψ

- Retrospective review of 184 patients with cisplatin-resistant, progressive GCT's
- 173 received 2 cycles of VeIP, then HDC
- 11 received 1 cycle of VeIP, then HDC
- Primary endpoint
   Disease Free Survival
- Secondary endpoint
  - Overall survival

Einhorn LH, et al. NEJM. 2007;357:340-8.

Patient Characteristics	Number of patients (%)
# of previous chemo regimens	
1	135 (73.4)
2	45 (24.4)
3	4 (2.2)
Response to initial chemotherapy	
CR	75 (40.8)
PR	9 (4.9)
< CR or PR with normal tumor markers	100 (54.3)
Initial IGCCCG stage (risk)	
Low	71 (38.6)
Intermediate	38 (20.7)
High	75 (40.8)


Einhorn LH, et al. NEJM. 2007;357:340-8.

oxicities [	ψ			
Grade 3 and higher toxicities	# of Patients			
Late Hematologic (leukemia)	3			
Renal (creatinine ↑'d 3-6 x ULN)	4			
Gastrointestinal	30			
Hepatic	6			
Neurologic	9			
Pulmonary	3			
2 deaths were associated with leukemia 2 deaths were associated with hepatic dysfunction 1 death was associated with pulmonary toxicities HDC with PBSCT can cure metastatic GCT's when used as				


SALVAGE CHEMOTHERAPY WITH PBSCT: <u>RESULTS*</u>			
	<u>No. pts.</u>	No cont. NED (%)	
Entire series	184	116 (63%);	
		104 > 2 yr. cont. NED	
Currently NED	122 (6	6%) (4 Tax+Gem and 2 surg)	
Second-line Tx	135	94 (70%)	
Third-line or later	49	22 (45%)	
hCG > 1,000	22	14 (64%)	
Seminoma 35		26 (74%)	
Platinum refractory	40	18 (45%)	
*Einhorn LH, et al.: NEJM 357:10-18, 2007			

PROGNOSTIC VARIABLES				
Variable	Pts.	<u>Cont. NED (%)</u>	<u>p value</u>	
Second-line Tx	135	94 (69.6)	0.003	
Third-line or later	49	22 (44.9)		
Seminoma*	35	26 (74.3)	0.17	
Nonseminoma	149	90 (60.4)		
Platinum refractory	40	18 (45.0)	0.01	
Platinum sensitive	144	98 (68.1)		
*14 of 15 cont. NED as initial salvage therapy				


<u>PROGNOSTI</u>	C VA	RIAB	LES (cont'd)	<b>U</b>
<u>Variable</u>		Pts.	Cont. NED (%)	<u>p value</u>
Response to initial chemo C.R. or P.R. marker neg > < C.R. or P.R. marker neg		84 100	61 (72.6) 55 (55.0)	0.015
Initial IGCCC stage Good-risk Intermediate	38	71	54 (76.1) 24 (63.2)	0.006
Advanced	50	75	38 (50.7)	




STRATIFICATION USING <u>3 VARIABLE RULE</u>					
<ul> <li>Score of 3 for third-line or later chemotherapy, 2 for advanced IGCCG stage, and 2 for platinum refractory</li> </ul>					
<u>7)</u>	<u>Good (0)</u>	Interm	ediate (2-3)	<u>Poor (4-</u>	
Number pts.	73		64	47	
DFS (%) (40%)	80 (79	9%)	26 (62%)	10	



HDC vs. CDC						
(Number of patients)	2 year PFS (%)	5 year OS (%)				
All patients (1594)	49.6 vs. 27.8	53.2 vs. 40.8				
HDC vs. CDC	P < 0.001	P < 0.001				
Very low risk (76)	91.6 vs. 58.4	88.7 vs. 64.5				
HDC vs. CDC	P < 0.008	P < 0.007				
Low risk (257)	64.3 vs. 40	64.5 vs. 66.2				
HDC vs. CDC	P < 0.001	P = 0.901				
Intermediate risk (546)	53.5 vs. 31.9	58.3 vs. 45.5				
HDC vs. CDC	P < 0.001	P < 0.002				
High risk (351)	33.3 vs. 17.2	35.2 vs. 23				
HDC vs. CDC	P < 0.001	P < 0.001				
Very high risk (105)	22 vs. 1.9	27 vs. 3.4				
HDC vs. CDC	P < 0.001	P < 0.002				
Lorch A, et al. J Clin Oncol. 2010;28:15S:4513.						



HIGH DOSE CHEMOTX – FIRST RELAPSE*							
	No.	2 yr.	5 yr.				
	Pts.	<u>PFS (%)</u>	survival (%)				
Single transplant	408	44.1	46.3				
		_ p<	p< 0.001 p< 0.001				
Sequential transplant	413	55.0	60.6				
Carbo + etoposide (CE)	301	57.6	62				
CE + Ifos	95	30.9	34.9				
CE + Thiotepa	102	40.0	43.9				
CE + Cyclophosphamide	212	53.5	55.9				
Other	111	45.1	49.4				
*Lorch A, et al.: JCO 29:2178-2184, 2011							



#### SINGLE VERSUS TRIPLE TRANSPLANT\*

• Sequential Versus Single High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: Long-Term Results of a Prospective Randomized Trial

Ψ

ψ

- Anja Lorch, et al JCO.2011.40.4160
- CONCLUSION: Patients with relapsed or refractory GCT achieve durable long-term survival after single as well as sequential HDCT.
   Fewer early deaths related to toxicity translated into superior longterm OS after sequential HDCT.

# SALVAGE HIGH DOSE CHEMOTHERAPY: SEMINOMA Retrospective review of 48 consecutive patients with pure seminoma who received high dose chemotherapy with carboplatin + etoposide with peripheral blood stem cell transplant from 2/96 to 6/06 36 of 48 (75%) continuously NED, including 22 of 24 receiving this therapy as initial salvage chemotherapy.MFU 46 months (range 25-131 months) 4 of 48 (8%) treatment-related mortality, all in patients with 2 or more prior chemotherapy regimens

Agarwala et al: Amer J Clin Oncol 34:286-288,2011

ψ

#### HDCT for Testicular Tumors

- HDCT is a curative options for large number of patients with relapse GCT.
- HDCT can be curable in 25% of patients with platinum refractory disease.
- High dose Caboplatin and Etoposide are the mean drugs shown to be effective.
- Patients selection and post transplant surgical and maintenance therapy plays an important role in curing these patients.

#### Acknowledgement

- · Patients and their families.
- Nursing staff and other health care provider at IUH.
- The BMT team.
- Larry Einhorn.

